Meryl H Mendelson1, Jonathan A Bernstein2, Susan Gabriel1, Maria-Magdalena Balp3, Haijun Tian1, Jeffrey Vietri4, Mark Lebwohl5. 1. a Novartis Pharmaceutical Corporation , East Hanover , NJ , USA. 2. b Department of Medicine , University of Cincinnati , Cincinnati , OH , USA. 3. c Global HEOR, Novartis Pharma AG , Basel , Switzerland. 4. d Health Economics, Kantar Health , Horsham , PA , USA. 5. e Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York , NY , USA.
Abstract
PURPOSE: Data are lacking on the burden of chronic idiopathic urticaria (CIU) versus other dermatologic conditions. This analysis compared the burden of chronic urticaria (CU, proxy for CIU) with psoriasis. METHODS: Data from CU (N = 747) and psoriasis patients (N = 5107) came from 2010 to 2012 US National Health and Wellness Surveys. Outcomes included SF-12v2/SF-36v2 mental and physical component summary scores (MCS and PCS, respectively) and other health/activity-related measures. RESULTS: MCS score was 44.7 for CU, and 48.2, 44.7 and 44.3 for mild/moderate/severe psoriasis, respectively (US norm = 50). PCS score was 43.8 for CU, and 46.5, 44.1 and 40.3 for mild/moderate/severe psoriasis. Health utility score was 0.67 for CU, and 0.72, 0.67 and 0.65 for mild/moderate/severe psoriasis. More CU patients reported depression (39%), anxiety (42%) and sleep difficulties (50%) than psoriasis patients (any severity). Overall work impairment was 29% for CU, and 19%, 26% and 31% for mild/moderate/severe psoriasis. Activities impairment was 39% for CU, and 28%, 37% and 43% for mild/moderate/severe psoriasis. CU and psoriasis patients had frequent healthcare visits. CONCLUSIONS: Patients with CU had impaired mental/physical health and work/non-work activities, similar to moderate-to-severe psoriasis patients. Results suggest that better disease management of CU is needed. This analysis should also reflect the significant burden of CIU.
PURPOSE: Data are lacking on the burden of chronic idiopathic urticaria (CIU) versus other dermatologic conditions. This analysis compared the burden of chronic urticaria (CU, proxy for CIU) with psoriasis. METHODS: Data from CU (N = 747) and psoriasispatients (N = 5107) came from 2010 to 2012 US National Health and Wellness Surveys. Outcomes included SF-12v2/SF-36v2 mental and physical component summary scores (MCS and PCS, respectively) and other health/activity-related measures. RESULTS: MCS score was 44.7 for CU, and 48.2, 44.7 and 44.3 for mild/moderate/severe psoriasis, respectively (US norm = 50). PCS score was 43.8 for CU, and 46.5, 44.1 and 40.3 for mild/moderate/severe psoriasis. Health utility score was 0.67 for CU, and 0.72, 0.67 and 0.65 for mild/moderate/severe psoriasis. More CUpatients reported depression (39%), anxiety (42%) and sleep difficulties (50%) than psoriasispatients (any severity). Overall work impairment was 29% for CU, and 19%, 26% and 31% for mild/moderate/severe psoriasis. Activities impairment was 39% for CU, and 28%, 37% and 43% for mild/moderate/severe psoriasis. CU and psoriasispatients had frequent healthcare visits. CONCLUSIONS:Patients with CU had impaired mental/physical health and work/non-work activities, similar to moderate-to-severe psoriasispatients. Results suggest that better disease management of CU is needed. This analysis should also reflect the significant burden of CIU.
Entities:
Keywords:
Chronic hives; burden; health-related quality of life; skin disorders
Authors: M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp Journal: Allergy Date: 2017-07-10 Impact factor: 13.146
Authors: Min Sang Lee; Jiwon Yoon; Jiwoong Kim; Yoo Seob Shin; Hae Sim Park; Hyun Young Lee; Young Min Ye Journal: Allergy Asthma Immunol Res Date: 2020-07 Impact factor: 5.764